Abstract: 2-Deoxy-D-glucose (2-DG) is a synthetic glucose analog that acts as a competitive inhibitor of glucose metabolism. While extensively studied in oncology and virology, 2-DG has garnered significant attention in neuropharmacology, particularly for its potential in treating epilepsy and neuroinflammatory conditions. By inhibiting glycolysis, 2-DG targets the high metabolic demands of hyper-excitable neurons, effectively reducing seizure duration and progression in various preclinical models. Furthermore, 2-DG exhibits neuroprotective properties against excitotoxicity and oxidative injury, and it mitigates neuroinflammation in viral encephalitis models. Despite its therapeutic promise, the clinical translation of 2-DG is hindered by its poor pharmacokinetic profile and dose-dependent toxicities, including cardiotoxicity and hypoglycemia. Recent advancements in structure-activity relationship (SAR) studies have led to the development of lipophilic prodrugs, such as WP1122, which offer enhanced blood-brain barrier penetration and improved bioavailability. This review synthesizes current literature on the pharmacological activity, molecular mechanisms, SAR, limitations, and future perspectives of 2-DG in neuropharmacology and epilepsy.
1. Introduction
Epilepsy is a prevalent neurological disorder affecting up to 1.6% of the population, characterized by spontaneous, recurrent seizures resulting from the synchronous and abnormal discharge of neurons [1]. Traditionally, the pathophysiology of epilepsy has been attributed to synaptic dysfunction and ionic dysregulation. However, emerging evidence highlights the critical role of brain metabolism in regulating neuronal excitability. During a seizure, the metabolic rate of glucose and oxygen consumption increases dramatically, and neurons rely heavily on anaerobic glycolysis to meet their surging adenosine triphosphate (ATP) demands [1].
2-Deoxy-D-glucose (2-DG) is a synthetic derivative of glucose in which the 2-hydroxyl group is replaced by a hydrogen atom [3]. This structural modification allows 2-DG to enter cells and competitively inhibit glycolysis, thereby creating a state of energy depletion [2][5]. Originally investigated as a calorie restriction mimetic and an anticancer agent targeting the Warburg effect, 2-DG has recently been explored as a novel therapeutic approach in neuropharmacology. By mimicking the metabolic state induced by fasting or a ketogenic diet, 2-DG can suppress the hyper-excitable state of epileptic networks, offering a paradigm shift from traditional ion-channel or neurotransmitter-targeted antiepileptic drugs [1][6].
2. Pharmacological Activity
In the realm of neuropharmacology, 2-DG has demonstrated significant efficacy across multiple preclinical models of epilepsy, neurodegeneration, and neuroinflammation.
Anticonvulsant and Antiepileptic Effects: 2-DG has been shown to reduce epilepsy progression and act as a potent anticonvulsant. In vivo studies demonstrate that 2-DG blocks recurrent seizures in corneal 6 Hz-stimulation and audiogenic mouse models, as well as in kindling models of seizures [1]. Furthermore, acute administration of 2-DG effectively arrests 4-Aminopyridine (4-AP) induced neocortical seizures in mice, significantly reducing both the duration and amplitude of the seizures while decreasing extracellular potassium accumulation [1]. The antiepileptic effect is partly mediated by NRSF-CtBP-dependent metabolic regulation of chromatin structure [1][2].
Neuroprotection: Beyond epilepsy, 2-DG acts as a calorie restriction mimetic that confers neuroprotection. It protects hippocampal neurons against excitotoxic and oxidative injury by upregulating stress response proteins such as heat shock protein 70 and glutamate-responsive protein-78 [4]. Additionally, 2-DG administration improves behavioral outcomes and reduces the degeneration of dopaminergic neurons in models of Parkinson's disease [4].
Anti-neuroinflammatory Effects: 2-DG also exhibits immunomodulatory properties in the central nervous system (CNS). In a mouse model of West Nile Virus (WNV) infection, which induces severe neuroinflammation, treatment with 2-DG alleviated CNS inflammation. It significantly reduced the expression of pro-inflammatory cytokines and chemokines, including Ccl2, Cxcl10, Cxcl11, and Tnf-α, thereby mitigating the neuroinflammatory response [7].
3. Molecular Mechanism of Action
The pharmacological effects of 2-DG in the nervous system are driven by a multi-faceted mechanism of action that disrupts cellular energy homeostasis and protein processing.
Inhibition of Glycolysis and ATP Depletion: 2-DG is transported into neurons and astrocytes via glucose transporters (GLUTs). Once intracellular, it is phosphorylated by hexokinase to form 2-deoxy-D-glucose-6-phosphate (2-DG-6-P) [3][5]. Unlike glucose-6-phosphate, 2-DG-6-P cannot be further metabolized by phosphoglucose isomerase. Consequently, it accumulates within the cell, non-competitively inhibiting hexokinase and competitively inhibiting phosphoglucose isomerase [3][5]. This catabolic block halts the glycolytic pathway, leading to a rapid depletion of intracellular ATP, which starves hyperactive neurons of the energy required to sustain synchronous epileptic discharges [1].
Inhibition of N-linked Glycosylation and ER Stress: Because 2-DG is a structural epimer of mannose, it interferes with mannose metabolism. It is converted into 2-DG-GDP, which competes with mannose-GDP, thereby inhibiting N-linked glycosylation of proteins in the endoplasmic reticulum (ER) [3][5]. This disruption leads to the accumulation of misfolded or unfolded glycoproteins, triggering ER stress and activating the Unfolded Protein Response (UPR) [2][5].
AMPK Activation and Autophagy: The dual insults of ATP depletion and ER stress activate AMP-activated protein kinase (AMPK) [3]. AMPK activation subsequently inhibits the mammalian target of rapamycin (mTOR) pathway, leading to the induction of autophagy or, under severe stress, apoptosis [2][3].
Oxidative Stress Modulation: By blocking glycolysis, 2-DG also shunts metabolism away from the pentose phosphate pathway (PPP), reducing the production of NADPH. Since NADPH is crucial for maintaining antioxidant defenses (e.g., glutathione reduction), 2-DG treatment can increase cellular susceptibility to oxidative stress [3][5].
4. Structure-Activity Relationship (SAR)
Modifications to the 2-DG scaffold have been extensively explored to enhance its pharmacokinetic properties, blood-brain barrier (BBB) penetrability, and target affinity.
Halogenation at C-2: Replacing the hydrogen atom at the C-2 position with halogens alters the molecule's affinity for hexokinase. For instance, 2-fluoro-2-deoxy-D-glucose (2-FDG) is a more potent inhibitor of glycolysis than 2-DG. The fluorine atom is conformationally and energetically more similar to a hydroxyl group, allowing 2-FDG-6-P to bind more effectively to the allosteric site of hexokinase [3]. The glycolytic inhibitory potency decreases with the increasing size of the halogen substituent (F > Cl > Br) [3]. However, because 2-FDG lacks structural similarity to mannose, it does not interfere with N-linked glycosylation, thereby losing the ER stress-mediated mechanisms of action present in 2-DG [3].
O-Acetylation (Prodrugs): 2-DG is highly hydrophilic, which limits its passive diffusion across the BBB and cellular membranes. To overcome this, O-acetylated derivatives have been synthesized. WP1122 (3,6-di-O-acetyl-2-deoxy-D-glucose) features acetoxy groups at carbons 3 and 6 [3]. This modification significantly increases the lipophilicity of the molecule, allowing it to cross the BBB via passive diffusion rather than relying solely on GLUT transporters [3]. Once inside the target cells, intracellular esterases cleave the acetyl groups, releasing the active 2-DG molecule. In vivo studies demonstrate that WP1122 achieves much higher tissue and organ concentrations and possesses a longer half-life compared to unmodified 2-DG [2].
5. Current Limitations
Despite its therapeutic potential, the clinical application of 2-DG is constrained by several significant limitations:
Toxicity and Adverse Effects: High doses of 2-DG are required to outcompete endogenous glucose, which can lead to systemic toxicity. Chronic ingestion of 2-DG has been shown to induce cardiac vacuolization and increase mortality in animal models [4]. In human clinical trials, 2-DG administration has been associated with hypoglycemia-like symptoms (sweating, flushing, dizziness), gastrointestinal bleeding, muscle weakness, and QTc prolongation [2][5][8].
Pharmacokinetic Challenges: 2-DG possesses poor "drug-like" properties, including a very short half-life and rapid metabolism. It is difficult to achieve and maintain the necessary therapeutic concentrations in the brain without administering doses that cause systemic toxicity [2][7].
Proconvulsant Risks in Specific Contexts: While 2-DG is anticonvulsant in many models, it can be proconvulsant in others (e.g., electroshock, pentylenetetrazol, and kainic acid models) [1]. Chronic hypometabolism induced by continuous 2-DG administration can decrease the efficacy of the GABAergic inhibitory system, potentially initiating epileptogenesis or lowering the seizure threshold [1].
6. Future Perspectives
To harness the neuropharmacological benefits of 2-DG while mitigating its drawbacks, future research is directing towards several innovative strategies:
Prodrug Development: The use of lipophilic prodrugs like WP1122 represents a highly promising avenue. By improving BBB penetration and cellular uptake, prodrugs can deliver effective concentrations of 2-DG to the brain at lower systemic doses, thereby reducing peripheral toxicity [2][3].
Combination Therapies: Because blocking glycolysis can lead to catastrophic energy failure and neuronal death, co-administering 2-DG with alternative metabolic substrates is a rational therapeutic strategy. Combining 2-DG with ketone bodies, such as beta-hydroxybutyrate (BHB), or a ketogenic diet can provide essential metabolic support to healthy neurons via the tricarboxylic acid (TCA) cycle, while selectively starving hyper-excitable epileptic neurons that rely strictly on anaerobic glycolysis [1][6].
Targeted Delivery Systems: Developing nanoparticle-mediated delivery systems or glycoconjugation strategies could further enhance the tissue-specific targeting of 2-DG to epileptic foci or neuroinflammatory sites, minimizing off-target effects and maximizing therapeutic index [3][6].
